Skip to main content
. 2022 Oct 3;132(19):e163614. doi: 10.1172/JCI163614

Figure 1. T cell immune response in individuals who received NVX-CoV2373 vaccine.

Figure 1

Individuals who received one or two doses of the protein-based NVX-CoV2373 vaccine exhibited increased levels of SARS-CoV-2 spike–specific CD4+ T cells, circulating Tfh cells, CD8+ T cells, and serum neutralizing antibodies. Spike-specific CD4+ T cell frequency correlated with the SARS-CoV-2–neutralizing antibody titers. Spike-specific CD4+ T cell response was present in most of the individuals who received one or two doses of NVX-CoV2373 vaccine, while a smaller proportion of vaccinees displayed spike-specific circulating Tfh cells and spike-specific CD8+ T cells.